TSND-201 (Methylone) for the Treatment of PTSD: Improvements across each CAPS-5 Cluster and Anxiety Symptoms from the Open-Label Portion of the IMPACT-1 Study

Summary of poster presentation: TSND-201 demonstrated rapid, robust, and consistent improvements across each PTSD symptom domain (Intrusion, Avoidance, Cognition and Mood, Arousal and Reactivity). Rapid and durable improvement on anxiety symptoms occurred concurrently with PTSD symptom improvement. TSND-201 was generally safe and well tolerated; the most common adverse events (AEs) were headache and decreased appetite. Randomized, placebo-controlled study is ongoing, with results expected in Q2 2025. View Poster

The release as fetched from its publisher. transcendtherapeutics.com ↗